SCHEDULE: FMR LLC Discloses 7.6% Stake in NewAmsterdam Pharma

FMR LLC and Abigail P. Johnson have jointly filed a Schedule 13G, reporting beneficial ownership of 8,765,811 shares, representing 7.6% of NewAmsterdam Pharma Company NV's common stock as of March 31, 2026.

Summary

• FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, indicating their beneficial ownership of 8,765,811 shares of NewAmsterdam Pharma Company NV common stock.
• This holding represents 7.6% of the total outstanding common stock as of the filing event date, March 31, 2026.
• FMR LLC is classified as a holding company (HC), while Abigail P. Johnson is classified as an investment advisor (IA).
• The filing confirms that FMR LLC has sole voting power over 8,755,902 shares and sole dispositive power over 8,765,811 shares.
• Abigail P. Johnson has sole dispositive power over 8,765,811 shares.
• The filing also notes that other persons have the right to receive or direct the sale of dividends from the shares, but no single other person's interest exceeds five percent.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It's a standard disclosure of beneficial ownership by a large institutional investor and does not provide new operational or financial information about the company itself.

Positives

• Significant institutional ownership by FMR LLC, a well-established financial services company.
• Clear disclosure of beneficial ownership, providing transparency to the market.
• The filing indicates that the securities were acquired and are held in the ordinary course of business, not for the purpose of influencing control.

Negatives

• The filing does not contain specific financial performance data or operational updates for NewAmsterdam Pharma Company NV, making it difficult to assess the company's underlying health.
• The disclosure is primarily an ownership update, not an operational or financial performance report.

Risks

• Potential for future changes in FMR LLC's stake, which could impact share price and liquidity.
• The filing does not provide details on the specific investment strategy or rationale behind FMR LLC's holdings in NewAmsterdam Pharma.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding NewAmsterdam Pharma Company NV's future performance. It solely reports on beneficial ownership.

Management Comments

• "This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the 'FMR Reporters')."
• "This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters..."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect..."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors like FMR LLC to disclose significant stakes in publicly traded companies. This filing indicates FMR LLC's continued interest or investment in the pharmaceutical sector, specifically in NewAmsterdam Pharma Company NV.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant institutional ownership, which can influence market perception and trading activity.
• Management of NewAmsterdam Pharma: Awareness of a substantial stake held by FMR LLC, potentially impacting strategic discussions or future corporate actions.
• Competitors: Insight into the investment activities of a major financial player within the pharmaceutical sector.

Next Steps

• Monitor future filings from FMR LLC and Abigail P. Johnson for any changes in their beneficial ownership of NewAmsterdam Pharma Company NV.
• Look for subsequent filings from NewAmsterdam Pharma Company NV for operational and financial updates.

Key Dates

Keywords

Schedule 13G, FMR LLC, Abigail P. Johnson, NewAmsterdam Pharma Company NV, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Investment Advisor, Holding Company